OR WAIT null SECS
Dr. Warrington discusses the details of glucocorticoids and how avacopan can help with the effective treatment of ANCA-associated vasculitis.
Kenneth Warrington, MD, is Chair of the Division of Rheumatology, Department of Internal Medicine at Mayo Clinic in Rochester, Minnesota with a joint appointment in the Gonda Vascular Center. In addition to that, he serves as director of the Vasculitis Subspecialty Group.
In this interview, Warrington shared how treatment of ANCA-associated vasculitis has progressed. He elaborated on how avacopan (Tavneos), the new therapeutic option for these patients can help reduce glucocorticoid use.
"ANCA vasculitis oftentimes is a very serious illness, and really, up until the 1980s, or so had a very high mortality rate of close to 90%," Warrington explained. "So, fortunately, advances in treatment have really transformed this from a fatal condition to one that is more of a chronic and treatable condition."
Warrington led a discussion with Tanaz Kermani, MD, MS, Division of Rheumatology, UCLA, and Matthew Koster, MD, Mayo Clinic Rheumatology, for a program called Institutional Perspectives in Rheumatology: ANCA-associated Vasculitis, as part of HCPLive’s® State of the Science series.